Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up.
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up.
复制标题
DOI：
10.1007/s10549-012-2315-y
复制
发表时间：
2012-12
影响因子：
3.8
通讯作者：
Arpino G
中科院分区：
文献类型：
--
作者：
Malorni L;Shetty PB;De Angelis C;Hilsenbeck S;Rimawi MF;Elledge R;Osborne CK;De Placido S;Arpino G
缺乏对大量特征明确的雌激素受体（ER）/孕激素受体（PgR）/HER 2阴性[三阴性（TN）]乳腺癌（BC）患者进行长期随访的研究。在这项研究中，我们分析了TN BC的临床结果和表皮生长因子受体（EGFR）表达的影响。比较了253例TN与1,036例ER阳性、PgR阳性、HER 2阴性[雌激素驱动的（艾德）] BC的临床和生物学特征、首次复发时间（TTFR）和总生存期（OS）。与艾德相比，TN肿瘤更大（p = 0.02），更具增殖性（高S期54 vs. 17%，p < 0.0001），更多的非整倍体（64 vs. 43%，p < 0.0001）和更可能的EGFR阳性（放射性配体结合分析≥10 fmol/mg，49 vs. 7%，p < 0.0001）。在TN中，EGFR阳性的BC比EGFR阴性的BC更大（p = 0.0018）、更增殖（p < 0.0001）和更多非整倍体（p < 0.0001）。与艾德患者相比，接受辅助治疗的TN患者的TTFR（p = 0.0003）和OS（p = 0.0017）较短。然而，在未经治疗的患者中，中位随访8年时，TTFR和OS没有观察到差异。在TN患者中，EGFR表达与预后不良无关。TN肿瘤在系统治疗的患者中具有更差的结果，但在未治疗的患者中并非如此。EGFR表达并不能预测更差的长期生存率。
Studies on well characterized, large populations of estrogen receptor (ER)/progesterone receptor (PgR)/HER2-negative [triple-negative (TN)] breast cancer (BC) patients with long-term follow-up are lacking. In this study, we analyze clinical outcomes of TN BC and implications of epidermal growth factor receptor (EGFR) expression. Clinical and biologic features, time to first recurrence (TTFR), and overall survival (OS) were compared in 253 TN versus 1,036 ER positive, PgR positive, HER2-negative [estrogen-driven (ED)] BC. Compared to ED, TN tumors were larger (p = 0.02), more proliferative (high S-phase 54 vs. 17 %, p < 0.0001), more aneuploid (64 vs. 43 %, p < 0.0001) and more likely EGFR positive (≥10 fmol/mg by radioligand-binding assay, 49 vs. 7 %, p < 0.0001). Among TN, EGFR-positive BC were larger (p = 0.0018), more proliferative (p < 0.0001), and more aneuploid, (p < 0.0001) than EGFR-negative BC. Adjuvant-treated TN patients had shorter TTFR (p = 0.0003), and OS (p = 0.0017), than ED patients. However, in untreated patients, no differences in TTFR and OS were observed at 8 years median follow-up. Among TN patients, EGFR expression was not associated with worse outcome. TN tumors have a worse outcome in systemically treated patients but not in untreated patients. EGFR expression, does not predict for worse long-term survival.
登录
查看更多内容
影响因子：
3.8
作者：
Hartog, Hermien;Horlings, Hugo M.;Wesseling, Jelle
通讯作者：
Wesseling, Jelle
影响因子：
8.4
作者：
Nicholson, RI;Gee, JMW;Harper, ME
通讯作者：
Harper, ME
影响因子：
45.3
作者：
Dawood, Shaheenah;Broglio, Kristine;Giordano, Sharon H.
通讯作者：
Giordano, Sharon H.
影响因子：
45.3
作者：
Huo, Dezheng;Senie, Ruby T.;Olopade, Olufunmilayo I.
通讯作者：
Olopade, Olufunmilayo I.
影响因子：
6.4
作者：
Bertucci, Francois;Finetti, Pascal;Birnbaum, Daniel
通讯作者：
Birnbaum, Daniel